2012-09-18 08:10:25 - New Pharmaceuticals market report from Global Markets Direct: "Kidney Fibrosis - Pipeline Review, H2 2012"

Global Markets Direct's, 'Kidney Fibrosis - Pipeline Review, H2 2012', provides an overview of the Kidney Fibrosis therapeutic pipeline. This report provides information on the therapeutic development for Kidney Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Fibrosis. 'Kidney Fibrosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the

indicated disease.


Full Report Details at
- www.fastmr.com/prod/463808_kidney_fibrosis_pipeline_review_h2_20 ..


Scope

* A snapshot of the global therapeutic scenario for Kidney Fibrosis.
* A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Kidney Fibrosis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Kidney Fibrosis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Kidney Fibrosis Therapeutic Products under Development, Key Players in Kidney Fibrosis Therapeutics, Kidney Fibrosis Pipeline Overview, Kidney Fibrosis Pipeline, Kidney Fibrosis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kidney Fibrosis Overview
Therapeutics Development
An Overview of Pipeline Products for Kidney Fibrosis
Kidney Fibrosis Therapeutics under Development by Companies
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Kidney Fibrosis Therapeutics - Products under Development by Companies
Companies Involved in Kidney Fibrosis Therapeutics Development
Bristol-Myers Squibb Company
BioLineRx, Ltd.
Paloma Pharmaceuticals, Inc.
Angion Biomedica Corp.
Thrasos, Inc.
Kidney Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CGEN-856 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THR-123 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Palomid 529 Oral - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-095 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
F351 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANG-3298 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kidney Fibrosis Therapeutics - Drug Profile Updates
Kidney Fibrosis - Product Development Milestones
Featured News & Press Releases
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan
Aug 26, 2010: GNI Receives F351 Patent Allowance in Canada
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Kidney Fibrosis, H2 2012
Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463808&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.